Dr. Reddy’s Laboratories announces the launch of Hervycta in India

Dr. Reddy’s Laboratories Ltd. has launched Hervycta (Trastuzumab), a biosimilar of Roche’s Herceptin in India, indicated for the treatment of HER2-positive cancers (early breast cancer, metastatic breast cancer, and metastatic gastric cancer). Dr. Reddy’s Hervycta is available in strengths of 150 mg and 440 mg multiple dose vials. Herceptin (marketed as Herclon in India) and its biosimilars had India sales of approximately `290 crore MAT for the most recent 12 months ending in December 2017, according to Ipsos. Dr. Reddy’s currently has four biosimilar products commercialized in India and various emerging markets, and an active pipeline of several biosimilar products in the oncology and immunology space.

“We strive every day to do what matters most for patients. Hervycta is a step forward in our effort to accelerate access to cancer patients in India, in the Oncology biosimilar space.”

MV Ramana
CEO – Branded Markets (India and Emerging Markets),
Dr. Reddy’s Laboratories